Company
Abbott
Last checked: Nov 19, 2026Source: Drugs@FDA, ClinicalTrials.gov
NDAs and BLAs
30
1 still marketed
Novel approvals
10
Approvals since 2021
0
Originals and new uses
Phase 3 trials
188
Registered, any status
Trials by phase
All registered drug and biologic trials with this lead sponsor, any status. A public view of the pipeline.
Recent approvals
Originals and efficacy supplements, newest first.
- Meridia new use Dec 8, 2005
- Depakote Er approved Dec 20, 2002
- Meridia new use Feb 16, 2001
- Meridia new use Feb 16, 2001
Drugs in development (1)
Investigational drugs, not yet FDA-approved, in this company's active or recent Phase 2 and 3 trials. Phase 3 first.
- AcotiamideItopride HydrochloridePhase 32 trials
Getz Pharma · Postprandial Distress Syndrome, Functional Dyspepsia
Recruiting Phase 3 trials
Largest first.
No recruiting Phase 3 trials under this sponsor name.
Marketed drugs (1)
Newest FDA action first.
- Depakote Er Divalproex Sodium · 2002
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.